Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Supernus Pharmaceuticals Inc shares valued at $1,008,150 were sold by Mottola Frank on Dec 19 ’25. At $50.41 per share, Mottola Frank sold 20,000 shares. The insider’s holdings dropped to 15,496 shares worth approximately $0.77 million following the completion of this transaction.
Also, FRANK MOTTOLA purchased 20,000 shares, netting a total of over 985,600 in proceeds.
Before that, Bhatt Padmanabh P. had sold 710 shares from its account. In a trade valued at $31,552, the Sr. VP of IP, CSO traded Supernus Pharmaceuticals Inc shares for $44.44 each. Upon closing the transaction, the insider’s holdings decreased to 710 shares, worth approximately $0.72 million.
As published in a research note from Piper Sandler on October 09, 2025, Supernus Pharmaceuticals Inc [SUPN] has been rated up from a Neutral to an Overweight and the price target has been revised to $65. Analysts at Cantor Fitzgerald upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in late July. As of February 19, 2025, Cantor Fitzgerald has decreased its “an Overweight” rating to a “Neutral” for SUPN. Earlier on January 06, 2025, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for SUPN stock.
Analyzing SUPN Stock Performance
On last trading session, Supernus Pharmaceuticals Inc [NASDAQ: SUPN] plunged -0.38% to $49.7. The stock’s lowest price that day was $49.32, but it reached a high of $50.1 in the same session. During the last five days, there has been a drop of approximately -3.89%. Over the course of the year, Supernus Pharmaceuticals Inc shares have jumped approximately 33.67%. Shares of the company reached a 52-week high of $57.65 on 10/30/25 and a 52-week low of $29.16 on 05/07/25.
Support And Resistance Levels for Supernus Pharmaceuticals Inc (SUPN)
According to the 24-hour chart, there is a support level at 49.31, which, if violated, would cause prices to drop to 48.93. In the upper region, resistance lies at 50.09. The next price resistance is at 50.49. RSI (Relative Strength Index) is 55.35 on the 14-day chart, showing neutral technical sentiment.
Is Supernus Pharmaceuticals Inc subject to short interest?
Stocks of Supernus Pharmaceuticals Inc saw a sharp steep in short interest on 2025-12-15 dropping by -0.39 million shares to 4.81 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 5.2 million shares. A decline of -8.1% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.26 of the overall float, the days-to-cover ratio (short ratio) decline to 7.26.
Which companies own the most shares of Supernus Pharmaceuticals Inc (SUPN)?
In terms of Supernus Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 63 in the next 12 months, up nearly 26.28% from the previous closing price of $49.89. Analysts anticipate Supernus Pharmaceuticals Inc stock to reach 65 by 2026, with the lowest price target being 55. In spite of this, 3 analysts ranked Supernus Pharmaceuticals Inc stock as Buy at the end of 2026. On September 11, 2024, Piper Sandler assigned a price target of “a Neutral” to the stock and downgraded coverage with a $36.
